Cardiovascular disease is the leading cause of death in developed, as well as develop ing, countries. Patients with key risk factors, and those who have a history of acute myo cardial infarction (MI), are at high risk of coronary events. The efficacy of secondary cardiovascular prevention therapy in these populations is well documented, but is ham pered by limited availability and inadequate prescription of medication, poor adherence to treatment, limited availability of medications, and unaffordable treatment costs. In his Viewpoint article, Lennart Forslund, from the Medical Products Agency in Uppsala, Sweden, points out that the implementation of a polypill requires a new way of thinking on aspects such as treatment paradigms, drug develop ment, and study design. Such changes in think ing will require interactions, not only between sponsors and regulatory agencies, but also the between the scientific community, healthcare systems and political systems as a whole.
A Review by Drs Guglietta and Guerrero from Ferrer Laboratories, Barcelona, Spain address the unique challenges in the pharmaceutical development of a cardiovascular polypill, such as the one they have developed for Centro Nacional de Investigaciones Cardiovasculares. The final decision on which, and how many, active drugs should be included in the Polypill depends on how developers prioritize clinical, pharmaceutical, and commercial issues.
In our Review, Ginés Sanz and I propose a threecomponent polypill, comprising aspirin, a statin, and an angiotensinconverting enzyme inhibitor for secondary prevention in patients who have already suffered an acute MI. The product is in the final stages of devel opment and will be made available at a price that will allow this Polypill to be accessible to patients in lowincome countries. Although Wald and Law originally proposed a pill com bining halfdoses of three antihypertensive drugs together with a statin, folic acid, and aspirin for primary prevention, our Polypill will include 100 mg aspirin, 40 mg simvastatin, and ramipril at three different doses (2.5 mg, 5 mg, and 10 mg), to facilitate dose titration. Our fixeddose combination therapy will be targeted towards highrisk patients who have had an MI and who should already have received these agents, as recommended by various guidelines. Although βblockers should be routinely administered in patients following MI, we decided do not include them in our Polypill, as the addition of a βblocker would increase the difficulties in galaenic for mulation and bioequivalence. Furthermore, a fourcomponent combined therapy would narrow the target population and increase the difficultly of dose titration.
Also in this issue of the journal, Salim Yusuf and colleagues describe the Indian Polycap Study, which comprehensively tests Wald and Law's hypothesis with a fivedrug combination as part of a multicenter, randomized, control led, doubleblind trial in a primary prevention setting. The 'Polycap' contains atenolol, thi azide, ramipril, simvastatin, and aspirin. Many will argue that this combination of agents is unnecessary for primary cardiovascular preven tion. A fixeddose polypill for use by patients with MI is, however, less controversial because each component is required for treatment of these individuals, adherence to therapy could be improved, and the cost of treatment could be reduced, thus making therapy more affordable in lowincome countries. 
